Treatment of Clonorchiasis in Guangxi With Albendazole, Tribendimidine, and Praziquantel

Launched by FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY · Jul 18, 2025

Keywords

ClinConnect Summary

This clinical trial is studying three different medicines—albendazole, tribendimidine, and praziquantel—to find out which works best and is safest for treating clonorchiasis. Clonorchiasis is an infection caused by a tiny parasite called a liver fluke, which people can get from eating raw or undercooked freshwater fish. The study will compare how well each medicine clears the infection by checking for parasite eggs in stool samples and will also look at any side effects people might experience.

Adults who have been diagnosed with clonorchiasis and meet certain health criteria may be eligible to join. Participants will be randomly given one of the three medicines and will need to provide stool samples before and after treatment to see if the infection is gone. If the infection remains, they may receive a second round of treatment. They will also have follow-up visits that include symptom checks, blood tests, and ultrasound scans to monitor liver health. Throughout the study, participants will be asked to report any side effects or discomfort. The results will help doctors choose the best treatment for clonorchiasis, making care safer and more effective.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Adults aged ≥18 years.
• • 2. Confirmed diagnosis of Clonorchis sinensis infection based on the latest Expert Consensus on Diagnosis and Treatment of Food-Borne Parasitic Diseases (2023): detection of eggs or adult worms in stool or bile drainage fluid.
• • 3. Willing and able to provide written informed consent and comply with study procedures.
• Exclusion Criteria:
• • 1. Known hypersensitivity or allergy to albendazole, praziquantel, or tribendimidine.
• • 2. Electrocardiogram (ECG)-confirmed supraventricular tachycardia or atrial fibrillation.
• • 3. Clinically or radiologically diagnosed neurocysticercosis (brain or spinal cord) or ocular cysticercosis (eye or orbit).
• • 4. Presence of gallbladder stones or biliary tract obstruction as confirmed by abdominal ultrasound.
• • 5. Individuals with severe hepatic, renal, or cardiac dysfunction, or with active peptic ulcer disease.
• • 6. Pregnant or breastfeeding individuals, or those of reproductive potential (male or female) who are unwilling to use effective contraception during the study period and for 3 months following the last dose of study medication.
• • 7. Anticipated loss to follow-up due to relocation, withdrawal of consent, or other factors affecting adherence to the study protocol.